Clinical Trials Logo

Filter by:
NCT ID: NCT03372070 Withdrawn - Snoring Clinical Trials

Continuous Negative External Pressure for the Treatment of Primary Snoring

Start date: January 2021
Phase: N/A
Study type: Interventional

The aim of this pilot study is to gain information on the ability of a continuous negative external pressure collar to safely reduce snoring in primary snorers, and if so to determine whether the reduction in snoring has benefits for both the snorer and the bed partner. This clinical trial will involve both the snorer and his or her bed partner, both of whom must qualify and provide informed consent for participation.

NCT ID: NCT03370978 Withdrawn - Text Messaging Clinical Trials

Text Messaging Follow-up From ED

Start date: May 1, 2019
Phase: N/A
Study type: Interventional

Ensuring follow-up for patients after discharge from the emergency department (ED) has long been a concern for ED care providers. The current technology of text messaging may be able to assist us in improving follow-up rates. In addition, having a quick and easy communication tool to be in touch with providers may improve overall patient satisfaction. This study is designed to evaluate the usage of text messaging to improve follow-up appointment compliance from the Emergency Department. In this study, a prospective randomized controlled trial (RCT) will be performed (involving patients scheduled by Emergency Department Nurse Navigators to follow up with Family Medicine) in which patients will be randomized to a texting appointment reminder versus standard-of-care (no texting reminder) group. Texted patients will receive reminders 3 days and 1 day prior to their follow-up appointment. In addition, the patients will have the ability to text back-and-forth with the Nurse Navigators in order to ask questions/request clarification if needed. Chart review will be performed of both groups to evaluate the number of follow-up appointments that patients attended versus rescheduled versus did not attend/reschedule. These values will then be compared to the retrospective chart review previously performed to evaluate for non-inferiority of text messaging as a means of improving patient attendance at follow-up appointments.

NCT ID: NCT03370185 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

BRIO
Start date: February 12, 2018
Phase: Phase 2
Study type: Interventional

This is a multi-center, single-arm, open-label, Phase 2 study of duvelisib, an orally bioavailable dual inhibitor of PI3K-δ,γ, in patients with CLL/SLL who have previously been treated with ibrutinib or another Bruton's Tyrosine Kinase Inhibitor (BTKi) and relapsed or were refractory to such therapy or discontinued such therapy due to toxicity.

NCT ID: NCT03370159 Withdrawn - Clinical trials for Stage IV Non-Small Cell Lung Cancer AJCC v7

CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

Start date: June 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of 6,8-bis(benzylthio)octanoic acid (CPI-613) when given together with docetaxel and to see how well they work in treating patients with stage IIIB or IV non-small cell lung cancer. Drugs used in chemotherapy, such as CPI-613 and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT03369964 Withdrawn - Clinical trials for Lymphoma, Non-Hodgkin

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Start date: March 14, 2018
Phase: Phase 1
Study type: Interventional

This study will investigate the safety, pharmacology, and activity of atezolizumab in combination with immunotherapy agents with or without an anti-CD20 agent (i.e., obinutuzumab) in patients with relapsed or refractory (R/R) follicular lymphoma (FL). The first immunotherapy molecule investigated will be emactuzumab (Arm A) in two combinations.

NCT ID: NCT03369639 Withdrawn - Depression, Anxiety Clinical Trials

Study of Dronabinol Treatment for Depression and/or Anxiety in Older Patients

Start date: November 28, 2017
Phase:
Study type: Observational

This is an observational study evaluating the safety and efficacy of dronabinol for the treatment of anxiety and/or depression in older adults. Participants who are prescribed dronabinol as part of a voluntary inpatient stay in McLean's Division of Geriatric Psychiatry will be interviewed about their mood and cognition on a weekly basis while on dronabinol.

NCT ID: NCT03369574 Withdrawn - Asthma Clinical Trials

Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab

Start date: November 14, 2017
Phase:
Study type: Observational

The primary objective of this research is to monitor chronic rhinosinusitis (CRS) symptoms in asthma patients who are undergoing treatment with reslizumab. A secondary objective is to explore whether there are sub-populations that appear to benefit or not benefit from reslizumab in terms of their CRS symptoms.

NCT ID: NCT03368534 Withdrawn - Chronic Wounds Clinical Trials

Autologous Regenerative Technology (ART) For Wound Healing

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

The purpose of the study is to provide a more effective method of harvesting skin with minimal or no pain, heal more rapidly with little scarring in an outpatient setting with the use of only local anesthesia.

NCT ID: NCT03368469 Withdrawn - Depressive Disorder Clinical Trials

Transcranial Direct Current Stimulation (tDCS) in Children and Adolescents With Epilepsy and Depression

Start date: February 23, 2018
Phase: N/A
Study type: Interventional

The proposed study seeks to obtain preliminary signal of the tolerability and efficacy of transcranial direct current stimulation (tDCS) for depressive symptoms in a sample of adolescents with depression and epilepsy. Additionally, effects of tDCS will be assessed via electroencephalographic, cognitive, and psychosocial measures.

NCT ID: NCT03365661 Withdrawn - Clinical trials for Myelodysplastic Syndrome

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

Start date: October 30, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II multi-institutional therapeutic study of a non-myeloablative T cell receptor (TCR) alpha/beta depleted haploidentical transplantation with post-transplant immune reconstitution using ALT-803 for the treatment of high-risk myeloid leukemia (AML), treatment-related/secondary AML, and myelodysplastic syndrome (MDS).